A real-world clustering analysis reveals heterogeneous response patterns to biologic therapy in severe asthma

Abstract

Aim: Despite the revolutionary impact of biologics (Bx) on severe asthma management, predicting individual treatment responses remains challenging. We aimed to characterize the heterogeneous nature of clinical status and disease activity in patients with severe asthma after biologic therapies through a comprehensive evaluation of real-world clinical outcomes. Methods: In this retrospective, multicenter study of 53 patients with severe asthma who received biologic therapies, hierarchical clustering analysis was performed based on three key parameters during treatment: exacerbation, maintenance oral corticosteroid (mOCS) dose, and lung function. Canonical correlation analysis and multinomial logistic regression were used to identify predictors of response patterns. Results: Clustering analysis revealed three distinct control groups: well-controlled (n=23), moderately controlled (n=22), and poorly controlled (n=8). Well-controlled patients exhibited minimal exacerbations, no oral corticosteroid (OCS) use, and optimal or stabilized lung function. Moderately controlled patients showed minimal exacerbations and no mOCS use but variable lung function improvements. Poorly controlled patients exhibited persistent exacerbations, mOCS dependence, or both with limited lung function improvement. Baseline forced expiratory volume in 1 second (FEV₁) %predicted (percent predicted FEV₁) values and blood eosinophil counts independently differentiated well-controlled from moderately controlled patients, whereas baseline mOCS use distinguished moderately controlled from poorly controlled patients. Conclusions: Our findings reveal distinct patterns of disease control following biologic therapy in severe asthma, with baseline lung function, eosinophilic inflammation, and OCS use as key predictive factors. These results support the need for personalized treatment approaches in severe asthma management.

Keywords

Severe asthma / biologics / cluster analysis / treatment response

References

[1] Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014; 43: 343-73.

[2] Israel E, Reddel HK. Severe and Difficult-to-Treat Asthma in Adults. N Engl J Med. 2017; 377: 965-76.

[3] Settipane RA, Kreindler JL, Chung Y, Tkacz J. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States. Ann Allergy Asthma Immunol. 2019; 123: 564-72.e3.

[4] Nagase H, Adachi M, Matsunaga K, Yoshida A, Okoba T, Hayashi N, et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. 2020; 69: 53-60.

[5] Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. N Engl J Med. 2022; 386: 157-71.

[6] Salter B, Lacy P, Mukherjee M. Biologics in Asthma: A Molecular Perspective to Precision Medicine. Front Pharmacol. 2022; 12: 793409.

[7] Gerday S, Graff S, Moermans C, Guissard F, Paulus V, Henket M, et al. Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline. Thorax. 2023; 78: 1138-41.

[8] Hanania NA, Castro M, Bateman E, Pavord ID, Papi A, FitzGerald JM, et al. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction. Ann Allergy Asthma Immunol. 2023; 130: 206-14.e2.

[9] Djukanović R, Brinkman P, Kolmert J, Gomez C, Schofield J, Brandsma J, et al. ; SoMOSA study team and the U-BIOPRED study team. Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study. Am J Respir Crit Care Med. 2024; 210: 288-97.

[10] Wechsler ME, Scelo G, Larenas-Linnemann DES, Torres-Duque CA, Maspero J, Tran TN, et al. Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma. Am J Respir Crit Care Med. 2024; 209: 262-72.

[11] Scelo G, Tran TN, Le TT, Fagerås M, Dorscheid D, Busby J, et al. Exploring Definitions and Predictors of Response to Biologics for Severe Asthma. J Allergy Clin Immunol Pract. 2024; 12: 2347-61.

[12] Denton E, Hew M, Peters MJ, Upham JW, Bulathsinhala L, Tran TN, et al. ; ISAR LUMINANT Working Group. Real-world biologics response and super-response in the International Severe Asthma Registry cohort. Allergy. 2024; 79: 2700-16.

[13] Park SY, Lee SK, Song WJ, Kim MH, Ban GY, Kim JH, et al. Real-World Effectiveness of Biologics in Patients With Severe Asthma: Analysis of the KoSAR. Allergy Asthma Immunol Res. 2024; 16: 253-66.

[14] Nagase H, Suzukawa M, Oishi K, Matsunaga K. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergol Int. 2023; 72: 11-23.

[15] Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012; 18: 716-25.

[16] Varricchi G, Ferri S, Pepys J, Poto R, Spadaro G, Nappi E, et al. Biologics and airway remodeling in severe asthma. Allergy. 2022; 77: 3538-52.

[17] Siddiqui S, Bachert C, Bjermer L, Buchheit KM, Castro M, Qin Y, et al. Eosinophils and tissue remodeling: Relevance to airway disease. J Allergy Clin Immunol. 2023; 152: 841-57.

[18] Varricchi G, Brightling CE, Grainge C, Lambrecht BN, Chanez P. Airway remodelling in asthma and the epithelium: on the edge of a new era. Eur Respir J. 2024; 63: 2301619.

[19] Kavanagh JE, Hearn AP, Dhariwal J, d’Ancona G, Douiri A, Roxas C, et al. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. Chest. 2021; 159: 496-506.

[20] Yamada M, Motoike IN, Kojima K, Fuse N, Hozawa A, Kuriyama S, et al. Genetic loci for lung function in Japanese adults with adjustment for exhaled nitric oxide levels as airway inflammation indicator. Commun Biol. 2021; 4: 1288.

[21] Hansen S, Baastrup Søndergaard M, von Bülow A, Bjerrum AS, Schmid J, Rasmussen LM, et al. Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies. Chest. 2024; 165: 253-66.

[22] Biener L, Mümmler C, Hinze CA, Suhling H, Korn S, Fisser C, et al. Real-World Data on Tezepelumab in Patients With Severe Asthma in Germany. J Allergy Clin Immunol Pract. 2024; 12: 2399-407.e5.

[23] Hamada Y, Thomas D, Harvey ES, Stevens S, Fricker M, Lewthwaite H, et al. Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma. Eur Respir J. 2025; 65: 2400782.

[24] Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013; 187: 804-11.

[25] Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. ; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371: 1198-207.

[26] Agustí A, Bafadhel M, Beasley R, Bel EH, Faner R, Gibson PG, et al. on behalf of all participants in the seminar. Precision medicine in airway diseases: moving to clinical practice. Eur Respir J. 2017; 50: 1701655.

[27] Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, et al. After asthma: redefining airways diseases. Lancet. 2018; 391: 350-400.

[28] Portacci A, Dragonieri S, Carpagnano GE. Super-Responders to Biologic Treatment in Type 2-High Severe Asthma: Passing Fad or a Meaningful Phenotype? J Allergy Clin Immunol Pract. 2023; 11: 1417-20.

[29] Mukherjee M, Forero DF, Tran S, Boulay ME, Bertrand M, Bhalla A, et al. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. Eur Respir J. 2020; 56: 2000117.

[30] Abdo M, Watz H, Veith V, Kirsten AM, Biller H, Pedersen F, et al. Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study. Respir Res. 2020; 21: 278.

[31] Suzukawa M, Ohta K, Fukutomi Y, Hashimoto H, Endo T, Abe M, et al. Classifications of moderate to severe asthma phenotypes in Japan and analysis of serum biomarkers: A Nationwide Cohort Study in Japan (NHOM Asthma Study). Allergol Int. 2023; 72: 63-74.

[32] Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021; 184: 1469-85.

[33] Saito T, Ichikawa T, Numakura T, Yamada M, Koarai A, Fujino N, et al. PGC-1α regulates airway epithelial barrier dysfunction induced by house dust mite. Respir Res. 2021; 22: 63.

[34] Itakura K, Fujino N, Kamide Y, Saito I, Yamada M, Okutomo K, et al. Decreased expression of airway epithelial Axl is associated with eosinophilic inflammation in severe asthma. Allergol Int. 2022; 71: 383-94.

[35] Gauthier M, Kale SL, Oriss TB, Gorry M, Ramonell RP, Dalton K, et al. CCL5 is a potential bridge between type 1 and type 2 inflammation in asthma. J Allergy Clin Immunol. 2023; 152: 94-106.e12.

[36] Fahy JV, Jackson ND, Sajuthi SP, Pruesse E, Moore CM, Everman JL, et al. Type 1 Immune Responses Related to Viral Infection Influence Corticosteroid Response in Asthma. Am J Respir Crit Care Med. 2025; 211: 194-204.

[37] Calzetta L, Aiello M, Frizzelli A, Bertorelli G, Rogliani P, Chetta A. Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence. Int J Mol Sci. 2021; 22: 7132.

[38] Menzies-Gow A, Gurnell M, Heaney LG, Corren J, Bel EH, Maspero J, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022; 10: 47-58.

[39] Fujino N, Ota C, Takahashi T, Suzuki T, Suzuki S, Yamada M, et al. Gene expression profiles of alveolar type II cells of chronic obstructive pulmonary disease: a case-control study. BMJ Open. 2012; 2: e001553.

[40] Kyogoku Y, Sugiura H, Ichikawa T, Numakura T, Koarai A, Yamada M, et al. Nitrosative stress in patients with asthma-chronic obstructive pulmonary disease overlap. J Allergy Clin Immunol. 2019; 144: 972-83.e14.

[41] Matsunaga T, Sano H, Takita K, Morita M, Yamanaka S, Ichikawa T, et al. Supersulphides provide airway protection in viral and chronic lung diseases. Nat Commun. 2023; 14: 4476.

[42] Wu TD, Diamant Z, Hanania NA. An Update on Patient-Reported Outcomes in Asthma. Chest. 2024; 165: 1049-57.

[43] Hyland ME, Jones RC, Lanario JW, Masoli M. The construction and validation of the Severe Asthma Questionnaire. Eur Respir J. 2018; 52: 1800618.